Showing results (31-40 of 201) with videos related to

Sort By:
Pageof 21
Psoriasis (Auckland, N.Z.)|August 17, 2022
Reducing the Risk of Developing Psoriatic Arthritis in Patients with PsoriasisPaolo Gisondi, Francesco Bellinato, Martina Maurelli, et al.
Psoriasis (Auckland, N.Z.)|September 29, 2025
Vunakizumab for Treatment of Acrodermatitis Continua of Hallopeau: A Case Report and Literature ReviewYi Yao, Yingming Ma, Huajie Zhong, et al.
Psoriasis (Auckland, N.Z.)|August 12, 2025
Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 yearsLuca Mastorino, Paolo Dapavo, Martina Burlando, et al.
Psoriasis (Auckland, N.Z.)|August 25, 2021
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World ScenariosMurlidhar Rajagopalan, Sunil Dogra, Abir Saraswat, et al.
Psoriasis (Auckland, N.Z.)|July 21, 2025
Tobacco Smoking Was Positively Associated with Disease Relapse at week 24 and 48 Among Patients with Psoriasis Vulgaris in Shanghai: A Prospective StudyFanlingzi Shen, Yuning Ding, Yan Qiang, et al.
Psoriasis (Auckland, N.Z.)|July 2, 2025
Evolution of Drug Supply for Psoriasis from 2010 to 2022 - Real-World Claims Data Analysis in GermanyKristina Hagenström, Theresa Klinger, Brigitte Stephan, et al.
Psoriasis (Auckland, N.Z.)|December 8, 2025
PEGylated Peptide for Targeted Inhibition of Human Antigen R as a Novel Therapeutic Strategy for Psoriasis: A Proof-of-Concept StudyYu-Fon Chen, Yi-Sheng Jiang, Yi-Cheng Chen, et al.
Psoriasis (Auckland, N.Z.)|March 6, 2025
Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World AnalysisFrederik Krefting, Cosima Scheib, Sven Benson, et al.
Psoriasis (Auckland, N.Z.)|December 2, 2024
Impact of IL-17A Inhibitors on Serum Uric Acid Levels in Psoriatic Patients with Hyperuricemia: A Prospective Observational StudyChao Wu, Chunxia He, Haimeng Wang, et al.
Psoriasis (Auckland, N.Z.)|July 1, 2024
Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, RomaniaStefana Bucur, Elena-Daniela Serban, Bogdan Vasile Ileanu, et al.
Pageof 21